Simple, Sensitive, and Scalable Patient Monitoring with the QuantideX^® qPCR BCR-ABL IS Kit (AMP 2019)

The emergence of new treatments and management approaches in chronic myeloid leukemia (CML) has generated long-term survival statistics that nearly mirror that of the general population. This longer-living and ever-growing patient population paired with the increased demand for detecting even deeper molecular responses now requires laboratories to implement a highly sensitive, scalable, and streamlined solution to keep up with increasing testing demands. In this workshop, we will review how the FDA-cleared, QuantideX^® qPCR BCR-ABL IS Kit not only arms laboratories with a simple and easy-to-implement solution for BCR-ABL monitoring today, but prepares them for the demands and challenges of tomorrow.